問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



National Taiwan University Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

Recruiting Trial

769Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

1621Cases

2017-03-01 - 2019-12-31

Phase III

Completed
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    學名：Pembrolizumab (MK-3475) ；商品名：KEYTRUDA®/吉舒達®

Participate Sites
6Sites

Terminated6Sites

陳訓徹
Linkou Chang Gung Medical Foundation

劉峻宇
Taipei Veterans General Hospital

Division of Hematology & Oncology

2023-01-27 - 2025-09-30

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting2Sites

Terminated2Sites

2023-01-30 - 2025-10-06

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting8Sites

2023-01-30 - 2026-05-29

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-01-30 - 2028-11-27

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2023-02-01 - 2028-01-31

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting6Sites

Recruiting4Sites

2023-02-15 - 2025-06-30

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting10Sites

2023-03-01 - 2026-12-31

Phase I/II

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
3Sites

Recruiting3Sites

2023-03-01 - 2025-10-12

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting1Sites

Terminated6Sites

2023-03-01 - 2029-05-01

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 11 12 13 14 15 163
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB